Cancer, Alzheimer’s, and other diseases follow a pathway in the human body. It starts at the molecular and cellular levels, and through a series of complex interactions can lead to the development and ...

Synthetic route design remains a critical bottleneck in small‑molecule drug discovery, especially as teams juggle complex targets, aggressive timelines, and sustainability expectations.

First set out in a scientific paper last September, Pathway’s post-transformer architecture, BDH (Dragon hatchling), gives LLMs native reasoning powers with intrinsic memory mechanisms that support ...